MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc Authors: Zihao Liu, Tingting Hu, Jie Min, Chen Wang, Yuhao Cao, Mengjie Guo, Jinjun Qian, Chunyan Gu, Ye Yang Published: 2026 ABSTRACT AbstractMultiple myeloma (MM) is an incurable malignancy characterized by clonal plasma cell proliferation, in which dysregulated ubiquitination plays a key pathogenic role. Using bufalin as a molecular probe, we identified melanoma-associated antigen C2 (MAGEC2) as a direct binding target and investigated its unconventional function beyond canonical E3 ligase modulation. MAGEC2 expression and clinical relevance were analyzed in patient cohorts. Functional assays (MTT, Western blot, CCK-8, flow cytometry) and mechanistic studies (co-immunoprecipitation, mass spectrometry, ubiquitination assays) were performed in vitro and in an adoptive B-cell transfer mouse model. High MAGEC2 expression was significantly associated with poor overall survival in MM patients. Functionally, MAGEC2 promoted malignant proliferation and induced resistance to adriamycin and bortezomib. Mechanistically, in addition to its known role in enhancing E3 ligase activity, MAGEC2 directly bound and increased the deubiquitinase activity of USP16, leading to c-Myc stabilization via reduced ubiquitination. Interactions among MAGEC2, USP16, and c-Myc were confirmed both in vitro and in vivo, establishing a MAGEC2-USP16-c-Myc axis. MAGEC2 overexpression also exacerbated bone lesions in vivo. Collectively, these findings identify MAGEC2 as both a prognostic biomarker and a promising therapeutic target in MM, and highlight its role as a multifunctional regulator of the ubiquitin system.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s40164-026-00782-4.Keywords: Multiple myeloma, MAGEC2, USP16, c-Myc, Ubiquitination To the Editor Traditional Chinese medicine (TCM) plays a significant role in the treatment of hematologic malignancies through its multi-target mechanisms [1, 2]. Bufalin, a bioactive compound derived from toad venom, exhibits potent anti-tumor effects but is limited by cardiotoxicity [3, 4]. In this study, we focused on bufalin as a molecular probe and identified MAGEC2 as a direct binding target in multiple myeloma (MM). The MAGE family of proteins is known to enhance E3 ubiquitin ligase activity [5], but the mechanisms underlying their upstream regulation remain unclear. Therefore, our study aimed to investigate whether MAGEC2 functions differently from conventional E3 ligase interactions and acts as a multifunctional regulator of the ubiquitin system. Dysregulated ubiquitination is a key factor in the pathogenesis of MM, driving proliferation and drug resistance [6]. By uncovering the non-canonical role of MAGEC2, our study aims to establish it as both a prognostic biomarker and a potential therapeutic target to overcome malignant progression in MM. Increased expression of MAGEC2 is associated with poor survival and aggressive proliferation in MM To investigate the functional role of bufalin, MTT assays confirmed that bufalin significantly inhibited MM cell viability (Fig. 1A). Using bufalin as a probe, we identified MAGEC2 as a direct molecular target (Fig. 1B), and microscale thermophoresis (MST) verified their strong, direct interaction with a binding affinity of 36.416 µM (Fig. 1C). To further explore the clinical implications of MAGEC2, we performed survival analysis using the KM-Plotter database, which includes a large cohort of MM patients treated with conventional induction chemotherapy, high-dose melphalan, and autologous stem cell transplantation. Our analysis revealed that among 806 patients with low MAGEC2 expression and 610 with high MAGEC2 expression, high MAGEC2 expression was associated with significantly reduced overall survival (P < 0.001) (Fig. 1D). Additionally, a pan-cancer analysis further showed frequent MAGEC2 upregulation across multiple malignancies, further supporting its pro-oncogenic role (Fig. 1E). Despite these associations, the specific biological function and mechanistic role of MAGEC2 in MM pathogenesis remain unclear. Increased expression of MAGEC2 is associated with poor survival and aggressive proliferation in MM. A Cell viability of ARP1, H929, KMS28-PE, and RPMI-8226 cells, treated with bufalin (0-400 µM), was analyzed using MTT assays. B HTPMS was employed to identify potential targets of bufalin in MM. C Direct interaction analysis between bufalin and MAGEC2 via MST with the calculated dissociation constant (Kd) value. D The KM-Plotter database analysis showed a significant association between MAGEC2 expression levels and overall survival in MM patients (P < 0.001). E The expression profile of MAGEC2 across multiple types of malignant tumors. F WB analysis was used to assess the efficiency of FLAG tag and MAGEC2 overexpression in stably transfected ARP1 and H929 cell lines. G The impact of MAGEC2 overexpression on the proliferation of ARP1 and H929 cells was analyzed using CCK-8. H Flow cytometric analysis was used to evaluate cell cycle progression in ARP1 and H929 cell lines following MAGEC2 overexpression. I MTT analysis was performed to assess drug resistance in ARP1 and H929 cells treated with ADR and BTZ (ADR: 0-100 µM, BTZ: 0-100 nM). J WB analysis was used to validate stable knockdown of MAGEC2 in ARP1 and H929 cell lines. K CCK-8 assays were used to evaluate the impact of MAGEC2 knockdown on the proliferation of ARP1 and H929 cell lines. L Flow cytometric analysis was used to assess the apoptosis rate in ARP1 and H929 MAGEC2-KD cell lines. Data are presented as mean ± standard error of mean (SEM). Differences between two groups were compared using Student’s t-test (two groups), while multiple groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. Significance levels are denoted as: ns (not significant), * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. All analyses were performed using GraphPad Prism 9.0.0 To address this gap, we conducted a comprehensive functional characterization of MAGEC2 in MM. We established and confirmed stable MAGEC2-overexpressing (MAGEC2-OE) ARP1 and H929 cell lines through Western blot (WB) analysis (Fig. 1F). Our CCK-8 assays demonstrated that MAGEC2 overexpression significantly enhanced proliferation in both ARP1 and H929 cells (Fig. 1G). Flow cytometry analysis of cell cycle distribution also revealed that MAGEC2 overexpression prolonged the G2/M phase in both cell lines (Fig. 1H). In MM treatment, Adriamycin (ADR) and bortezomib (BTZ) are commonly used drugs [7]. MTT assays showed that MAGEC2 overexpression conferred increased resistance to ADR and BTZ in ARP1 and H929 cells, suggesting a role for MAGEC2 in mediating drug resistance (Fig. 1I). Conversely, we established stable MAGEC2-knockdown (MAGEC2-KD) cell lines in ARP1 and H929 backgrounds, with efficient depletion of MAGEC2 protein validated by WB (Fig. 1J). CCK-8 assays revealed that MAGEC2-KD effectively suppressed proliferation in both cell lines (Fig. 1K), while flow cytometry analysis of apoptosis demonstrated an increase in apoptotic rates following MAGEC2-KD in ARP1 and H929 cells (Fig. 1L), highlighting its critical role in cell survival [8]. MAGEC2 promotes malignant proliferation of MM by enhancing USP16 deubiquitinase activity to stabilize c-Myc Previous studies have shown that MAGEC2 exerts oncogenic functions by enhancing the E3 ligase activity of RING-domain proteins, such as TRIM28, which promotes p53 degradation [9]. To identify additional downstream effectors, we performed ubiquitination-focused mass spectrometry and identified ribosomal protein s27A (RPS27A) and USP16 as the top candidates (Fig. 2A). To determine which protein serves as a more suitable downstream effector of MAGEC2, we conducted an integrated analysis using clinical databases. We collected peripheral blood samples from 22 normal plasma (NP) individuals, 44 patients with monoclonal gammopathy of undetermined significance (MGUS), and 351 patients with multiple myeloma (MM). Interestingly, the clinical signal abundance of RPS27A was higher in healthy controls compared to the MGUS and MM groups (P < 0.001) (Fig. 2B). Additionally, high expression of RPS27A was associated with better overall survival in MM patients (P < 0.05) (Fig. 2C). Although RPS27A ranked highly in our screen, its identity as a ubiquitous ribosomal structural protein [10] and its association with favorable clinical outcomes in MM patients suggest that it is unlikely to be a specific, direct effector in MAGEC2-driven oncogenesis. MAGEC2 promotes malignant proliferation of MM by enhancing USP16 deubiquitinase activity to stabilize c-Myc. A The top two downstream proteins of MAGEC2 were identified via ubiquitination-based MS sequencing. B Clinical signal values of the top-ranked protein RPS27A in NP, MGUS, and MM (P < 0.001). C Distinct overall survival in MM patients was associated with differential expression levels of RPS27A in both APEX (P < 0.05) and TT2 (P < 0.05) patient cohorts, as determined by Kaplan-Meier survival analysis. D The pan-cancer expression profile of the second-ranked protein, USP16. E The relationship between USP16 expression levels and clinical prognosis in patients with MM was evaluated using the KM-Plotter database (P < 0.05). F The protein-protein interaction (PPI) database revealed potential substrates that directly interact with USP16. G Co-IP was performed to investigate the potential endogenous interactions among MAGEC2, USP16, and c-Myc in ARP1 and H929 cells. H WB assay was conducted to assess USP16 and c-Myc protein expressions in ARP1 and H929 MAGEC2-OE cells. I WB analysis of USP16 and c-Myc expressions in ARP1 and H929 MAGEC2-KD cells. J Analysis of c-Myc protein deubiquitination level in ARP1 and H929 MAGEC2-OE cells via ubiquitination experiment. K The effect of MAGEC2 overexpression on the protein stability of USP16 and c-Myc in ARP1 and H929 cells was assessed by CHX chase assay using 50 µg/mL cycloheximide. L The effect of USP16 silencing on c-Myc deubiquitination in MAGEC2-OE cells was examined by ubiquitination assay following siRNA-mediated knockdown of USP16. M CHX chase analysis (50 µg/mL) of c-Myc stability in MAGEC2-OE cells following USP16 knockdown. N The direct interactions among MAGEC2, USP16, and c-Myc were assessed by in vitro SPR analysis, with corresponding Kd values. O Kaplan-Meier survival curve was plotted from survival data for mice in the EV and MAGEC2-OE groups (n = 8 per group, P < 0.001). P Representative micro-CT images of tibias and corresponding quantitative analysis of BV/TV and BMD in EV and MAGEC2-OE group mice (P < 0.001, P < 0.05). Data are presented as mean ± standard error of mean (SEM). Differences between two groups were compared using Student’s t-test (two groups), while multiple groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. Survival data were analyzed using the Kaplan-Meier method and the log-rank test. Significance levels are denoted as: ns (not significant), * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. All analyses were performed using GraphPad Prism 9.0.0 In contrast, USP16 was consistently upregulated across multiple tumor types (Fig. 2D). Using the same cohort of MM patients from the KM-Plotter database, USP16 overexpression was associated with a poorer overall survival rate in MM (P < 0.05) (Fig. 2E). This expression pattern, which aligns with a poor prognosis and suggests a potential oncogenic function, led us to select USP16 as a primary candidate downstream target of MAGEC2 for further investigation. As USP16 is a deubiquitinase, it may target multiple substrates. Through an integrated analysis of protein interaction databases and the existing literature, we identified a potential interaction between c-Myc and USP16 [11]. Previous studies have also confirmed that c-Myc is a critical oncogenic driver in MM. Based on these findings, we hypothesized that c-Myc may be a deubiquitination substrate of USP16 in MM (Fig. 2F). To verify this hypothesis, we performed Co-IP and confirmed interactions among MAGEC2, USP16, and c-Myc (Fig. 2G). The WB results further indicated that overexpression of MAGEC2 increased the protein levels of USP16 and c-Myc (Fig. 2H), whereas MAGEC2 knockdown in ARP1 and H929 cells reduced their levels (Fig. 2I). The results of ubiquitination assays showed that overexpression of MAGEC2 increased c-Myc deubiquitination (Fig. 2J). Additionally, cycloheximide chase assays revealed that both USP16 and c-Myc had extended half-lives (Fig. 2K). To investigate if MAGEC2 suppresses c-Myc ubiquitination by enhancing USP16’s deubiquitinase activity, we used small interfering RNA (siRNA) to silence USP16 expression in MAGEC2-overexpressing cells. The ubiquitination experiment confirmed our hypothesis that silencing USP16 reduces c-Myc deubiquitination levels (Fig. 2L), thereby decreasing c-Myc protein stability (Fig. 2M). We then purified recombinant MAGEC2, USP16, and c-Myc proteins and conducted surface plasmon resonance (SPR) analysis, which showed that USP16 directly interacts with both MAGEC2 and c-Myc with high affinity in vitro (Fig. 2N). To extend our cellular observations in vivo, we established adoptive B-cell transfer models via tail vein injection of splenocyte suspensions from MYCflox/flox·Cre+ mice into NOD-SCID recipients, co-administered with concentrated empty vector (EV) or MAGEC2-OE lentivirus. Survival curve analysis showed that mice with high MAGEC2 expression had significantly shorter overall survival compared to those in the EV group (P < 0.001) (Fig. 2O). We also used Micro-computed tomography (Micro-CT) imaging to examine tibias from the EV and MAGEC2 groups and found that the MAGEC2-OE group had lower bone volume fraction (BV/TV) (P < 0.001) and bone mineral density (BMD) (P < 0.05), indicating more severe bone lesions (Fig. 2P). In conclusion, our study identifies MAGEC2 as a target of bufalin that drives MM progression by enhancing USP16-mediated c-Myc deubiquitination. This pathway promotes proliferation, drug resistance, and bone lesions, highlighting MAGEC2 as a prognostic biomarker and therapeutic target, and emphasizing the use of natural compound-based probes for target discovery [12]. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1. Acknowledgements We would like to thank all members of the Multidimensional Intervention Laboratory for Malignant Tumors at Nanjing University of Chinese Medicine and Jiangsu Province Hospital of Chinese Medicine for their support of this study. Abbreviations Multiple myeloma Melanoma-associated antigen C2 High-throughput protein microarray screening Cellular myelocytomatosis oncogene Ubiquitin specific peptidase 16 Methylthiazolyldiphenyl-tetrazolium bromide Microscale thermophoresis Western blot Cell counting kit-8 Adriamycin Bortezomib Normal plasma Monoclonal gammopathy of undetermined significance Ribosomal protein s27a Co-immunoprecipitation Cycloheximide Small interfering RNA Surface plasmon resonance Empty vector Serum protein electrophoresis Micro–computed tomography Bone volume fraction Bone mineral density Immunohistochemical staining Mass spectrometry Agarose gel electrophoresis Polymerase Chain Reaction Syndecan-1 Author contributions Y.Y. and C.G. conceived and designed the study. Z.L. and T.H. contributed equally to this work. Z.L. drafted the manuscript. Z.L. and T.H. carried out the experiments and analyzed the data. T H. performed the MST and phenotypic analysis. J.M. and C.W. contributed to methodological refinement. Y.C. provided specialized software support and expertise for the analysis and validation of HTPMS. M.G. and J.Q. participated in formatting the manuscript and revising its content. All authors have reviewed, approved the final version of the manuscript, and agreed to its submission. Funding This work was supported by Climbing Plan of Basic Research Priorities Program of Jiangsu Province (BK20240003); a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Traditional Chinese Medicine; Integration of Chinese and Western Medicine). Data availability The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Nanjing University of Chinese Medicine. The animal experiments were specifically reviewed and approved by the institution’s Institutional Animal Care and Use Committee (IACUC) (Approval No. 202406A031). Consent for publication All authors have read and agreed to the publication of this manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zihao Liu and Tingting Hu have contributed equally to this work. Contributor Information Chunyan Gu, Email: guchunyan@njucm.edu.cn. Ye Yang, Email: yangye876@sina.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.